

Neal Adams, MD, MPH
Pacific Research Partners, LLC
1611 Telegraph Avenue, Suite 100 & Suite 1550
Oakland, CA 94612

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Site Liaison
Tel. (866) 669-0234
Fax (208) 575-3169
Email: clinicaltrials@btheodore.com

AFFILIATIONS:

Collaborative Neuroscience Network Phase I Unit
Long Beach, CA

Collaborative Neuroscience Network
Torrance, CA

Collaborative Neuroscience Network
Garden Grove, CA

American Association of Community Psychiatrists

American Psychiatric Association

California Psychiatric Association

Northern California Psychiatric Society

American College of Mental Health Administration

EDUCATION:

1974-1978 MD	Northwestern University
1977-1978 MPH	Harvard University
1970-1972 BA with Honors	University of California, Santa Cruz
1967-1969	University of California, Berkeley

FOREIGN LANGUAGE CAPACITY - Fluent in Spanish

INTERNSHIPS AND RESIDENCIES:

1981-1983 Robert Wood Johnson/Veteran's Administration Clinical Scholar,
Stanford University Medical Center/Palo Alto VA
1980-1982 Psychiatry Resident (PGY III-IV), Stanford University Medical Center
1979-1980 Psychiatry Resident (PGY II), Massachusetts Mental Health Center
1978-1979 Psychiatry Intern (PGY I), San Francisco General Hospital

LICENSURE AND CERTIFICATION:

American Board of Psychiatry and Neurology, Certificate # 32680
• sub-specialty certification in Addiction Psychiatry #1070 (*expired*)
National Board of Medical Examiners, Certificate # 194757
California License # G43003
New Mexico License # 92-169 (*inactive*)

PROFESSIONAL EXPERIENCE:

Sub-Investigator, 2010 - present
Pacific Research Partners, Oakland, CA

Associate Medical Director, 2009 - present
Optum Health Behavioral Health Solutions, San Francisco, CA

Advisory Committee/Faculty, 2006 - 2009
Petris Center, UC Berkeley School of Public Health, Berkeley, CA

Sub-Award Principle Investigator, 2005 - 2009
Petris Center, UC Berkeley School of Public Health, Berkeley, CA

Director of Special Projects, 2005 - 2009
California Institute for Mental Health, Sacramento, CA

Medical Director, 2001 - 2004
California Department of Mental Health, Sacramento, CA

Director, 2000 - 2001
Santa Cruz County Medical Health and Substance Abuse Services, Santa Cruz, CA

Accreditation Surveyor (part-time), 1996 - 2001
CARF...The Rehabilitation Commission, Tucson, AZ

PROFESSIONAL EXPERIENCE (continued):

Program Chief/Medical Director, 1998 - 2000
Santa Cruz County Mental Health, Santa Cruz, CA

Senior Physician Advisor (part-time), 1995 - 2000
Magellan Behavioral Health, After Hours Solutions Group, Columbia, MD

Medical Director, 1997 – 1998
Division of Health Improvement/Department of Health, State of New Mexico, Santa Fe, NM

Medical Director, 1993 – 1997
Division of Mental Health/Department of Health, State of New Mexico, Santa Fe, NM

Medical Director (part-time), 1995 – 1998
Ranch Valmora Residential Treatment Center, Valmora, NM

Clinical Director (Interim), 1994 – 1995
Las Vegas Medical Center, Las Vegas, NM

Utilization Review Consultant, 1994 – 1995
Blue Cross/ Blue Shield of New Mexico, Albuquerque, NM

Acting Medical Director/ Clinical Consultant, 1993 - 1994
Pinon Hills Residential Treatment Center, Velarde, NM

Director of Clinical Services, 1992 – 1993
Taos/Colfax Community Services, Inc., Taos, NM

Medical Director, 1991-1992
Southern Nevada Adult Mental Health Services, Las Vegas, NV

Acting Vice Chairman/Associate Professor of Clinical Medicine, 1991-1992
Department of Psychiatry and Behavioral Sciences
University of Nevada School of Medicine, Las Vegas, NV

Medical Director – Adult Services, 1990 – 1991
Solano Park Hospital, Fairfield, CA

CEO/Medical Director, 1989 – 1991
Ceregraphic Brain Imaging, Oakland, CA

Medical Director, 1983-1985
Pain Management Center, Los Medanos Hospital, Pittsburg, CA

PROFESSIONAL EXPERIENCE (continued):

Co-Director, 1983 – 1984

Psychiatric Specialists in Industry, San Francisco, CA

Regional Mental Health Consultant, 1981 – 1983

Job Corps Health Program, US Department of Labor, San Francisco, CA

INVESTIGATOR EXPERIENCE:

Attention Deficit Hyperactivity Disorder (ADHD) • Alzheimer's Disease • Anxiety

Bipolar Disorder • Depression • Eating Disorders • Epilepsy • Insomnia

Mania • Migraine • Obsessive Compulsive Disorder • Pain • PTSD/Trauma

Schizophrenia • Substance Abuse Disorders • Traumatic Brain Injury

CLINICAL TRIAL EXPERIENCE:

Depression

A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 mg XXX versus Placebo in Adult Subjects with Major Depressive Disorder Followed by a 52-week Open-label Extension

A Phase III, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of XXX in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant

A Phase IV, Multicenter, Randomized, 8-week, Double-blind, Placebo-controlled, Parallel-group, Study to Evaluate the Efficacy of Two Fixed Doses (50 and 100 MG/Day) of XXX in Adult Outpatients with Major Depressive Disorder (MDD)

A Phase III, , Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Efficacy and Safety Study of 3 Fixed Dose Groups of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy.

A Phase III, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of XXX in Subjects With Major Depressive Disorder

CLINICAL TRIAL EXPERIENCE (continued):

A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of XXX in Acute Treatment of Adults With Major Depressive Disorder

A Phase III, Randomized Placebo-Controlled, Double-Blind Study of XXX Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to XXX Treatment.

A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of XXX in Flexible Doses as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy.

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy

Schizophrenia

A Fifteen-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of XXX Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia Who Have Been Recently Released From Jail

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia

A Multicenter, Double-Blind Comparison of XXX and Aripiprazole in Patients with DSM-IV-TR Schizophrenia Followed by Open-Label Treatment with XXX

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of XXX versus Placebo in Patients with DSM-IV-TR Schizophrenia

A Long-Term, Open-Label, Multicenter Study of XXX Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of XXX Evaluating Time to Relapse in Subjects With Schizoaffective Disorder

CLINICAL TRIAL EXPERIENCE (continued):

A Randomized, 6-week, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of XXX for the Treatment of Schizophrenia or Schizoaffective Disorder in Subjects SWITCHED From Other Antipsychotic Agents *and* A 24-Week, Flexible-Dose, Open-label Extension Study of Subjects Switched to XXX for the Treatment of Schizophrenia or Schizoaffective Disorder

A 12-week, Randomized, Multicenter, Open-label, XXX Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving XXX or XXX

CLINICAL EMPLOYMENT/PRACTICE:

Private Practice <i>part time</i>		Santa Cruz, CA	2000-present
Psychiatric Consultant	New Mexico Boy's School	Springer, NM	1993
Private Practice		Berkeley, CA	1982-91
Psychiatric Consultant	Parnassus Heights Disability Consultants	San Francisco, CA	1986-89
Staff Psychiatrist	Contra Costa County Mental Health Services	Martinez, CA	1983
Staff Psychiatrist	Psychiatric Emergency	Oakland, CA	1982-84
	Highland General Hospital		1987-89
Psychiatric Consultant	Rehabilitation Mental Health Services	San Jose, CA	1981-83
Staff Psychiatrist	Santa Clara Valley Medical Center	San Jose, CA	1981-83
Staff Psychiatrist	Dorchester Mental Health Center	Boston, MA	1980
Staff Psychiatrist	Charles River Hospital	Wellesley, MA	1979-80
Staff Psychiatrist	St. Elizabeth's Hospital	Boston, MA	1979-80
Clinic Physician	Boston Methadone Treatment Program	Boston, MA	1979-80

COMMUNITY/ORGANIZATION SERVICE:

American Association of Community Psychiatrists	Board of Directors		2004-2007
ComPeer Santa Cruz	Board of Directors		2003-2004

COMMUNITY/ORGANIZATION SERVICE (continued):

Annapolis Coalition on Behavioral Health Workforce Education	Board of Directors	2001-2006
California Psychiatric Association	Public Psychiatry Committee	2002-2005
Santa Cruz Community Mental Health Summit	Honorary Chair	2002-2003
National Alliance for the Mentally Ill	TRIAD Project Advisory Board	2002-2004
California Institute for Mental Health	Medication Algorithm Implementation Steering Committee	2003-present
	Evidence Based Practices Initiative Steering Committee	2002-present
SAMHSA/Center for Mental Health Services	Co-Chair, Workgroup for Quality Chasm Implementation Resource Kit Planning Committee for a National Summit on Common Performance Indicators for Behavioral Health	1999-present
Annapolis Coalition for Behavioral Health Workforce Development	Executive Committee	2001-present
California Mental Health Director's Association	Representative to California DMH State Quality Improvement Committee	2000-2004
Mental Health Statistics Improvement Program (MHSIP)	Report card ver 2 workgroup	2001-2005
	National Advisory Group	1999-2005

COMMUNITY/ORGANIZATION SERVICE (continued):

American College of Mental Health Administration	President, ACMHA Foundation	2003-2005
	President	2001-2003
	Chair, Accreditation Organization Workgroup on Quality and Measurement	1998-2000
Human Services Research Institute (HSRI)	Board member-at-large	1997
	MHSIP Consumer Report Card Toolkit Workgroup	1998
National Association of State Mental Health Program Directors (NASMHPD)	President's Task Force Technical Advisory Workgroup	1997-98
CARF...The Rehabilitation Commission	National Advisory Committees on Behavioral Health Standards and Performance Measurement	1997- present
Center for Mental Health Services/SAMHSA	Public Sector Outcome Measurement Policy Steering Committee	1996-97
Nevada Mental Health Commission	Patient's Rights Task Force	1992
Family Services Agency of the North Bay	Board of Directors	1990-91
Volunteers in Service to America: VISTA	Rural Indiana Health Project	1973

ACADEMIC EMPLOYMENT/APPOINTMENTS/TRAINING:

Trainer	National Council for Community Behavioral Health	2004-present
	California Institute for Mental Health	2000-present
	CARF Regional and National Trainings in Treatment Planning for Better Outcomes	1997-present
Consultant/Trainer	Mental health and substance abuse services provider organizations on treatment planning, documentation quality management and outcome evaluation systems	1998-present

ACADEMIC EMPLOYMENT/APPOINTMENTS/TRAINING (continued):

Instructor	Drake University Extramural Programs Albuquerque, New Mexico	1995
Assistant Clinical Professor of Psychiatry	Department of Psychiatry University of New Mexico	1992-1997
Instructor	Area Health Education Council Las Vegas, New Mexico	1993-97
Associate Professor of Clinical Medicine	Department of Psychiatry and Behavioral Sciences University of Nevada School of Medicine	1991-1992
Educational Consultant	Burroughs-Wellcome Pharmaceuticals	1990-91
Teaching Fellow/Clinical Fellow	Massachusetts Mental Health Center Harvard University	1978

GRANTS, PROJECTS, PUBLICATIONS AND PAPERS:

Excess Non-Psychiatric Hospitalization Among Medi-Cal Beneficiaries with Serious Mental Illness in California, Co-Author, Psychiatric Services, 2008

Mental Health Corporation of America Quality Improvement Learning Collaborative Using the IOM 6 Aims, Co-Principle Investigator, for SAMHSA funded Learning Collaborative, 2007 – present

The Intersection of Transformation and Quality in Mental Health Treatment: Implementing the California Learning Collaborative, Co-Author, International Journal of Mental Health, 2007

A Scale to Assess Fidelity to Evidence-Based Principles of Medication Management For Schizophrenia, Co-Author, Schizophrenia Bulletin, 2007

The Intersection of Transformation and Quality in Mental Health Treatment: Implementing the California Learning Collaborative, Co-Author, International Journal of Mental Health, 2007

Monograph: *An Action Plan On Behavioral Health Workforce Development*, Co-Author, Annapolis Coalition on the Behavioral Health Workforce, Cincinnati, OH, 2007

Monograph: *International Pathways to Mental Health System Transformation*, Project Lead/Senior Editor, California Institute for Mental Health, 2007

Monograph: *From Study to Action: A Strategic Plan for Transformation of Mental Health Care*, Co-Author, California Institute for Mental Health, 2006

GRANTS, PROJECTS, PUBLICATIONS AND PAPERS (continued):

Millionaires And Mental Health: Proposition 63 In California, Co-Author, Health Affairs, Web Exclusive, 2005

Transforming Mental Health, Co-Editor vol 34:1 of International Journal of Mental Health, 2005

Book: *Person Centered Treatment Planning*, Author for Elsevier/Academic Press, 2004

Monograph: *From Policy to Service: A Quality Vision for Behavioral Health*, Co-Author, ACMHA/SAMHSA sponsored review of President's New Freedom Commission and IOM Quality Chasm reports, 2004

Grant: *Integrated Dual Diagnosis Treatment Toolkit Evaluation*, Principle Investigator for SAMHSA funded study, 2003-2006

Sometimes A Great Notion...A Common Agenda for Change, Administration and Policy in Mental Health, 2002

Monograph: *Turning Knowledge Into Practice*, Editorial board for AMCHA and Technical Assistance Collaborative, Inc., 2002-2003

Monograph: *Financing Results and Value in Behavioral Health Services*, Contributor for ACMHA, 2001-2003

Book Reviews: Hospital and Community Psychiatry, 2001-present

Monograph: *Proposed Set of Indicators for Behavioral Health*. Editor for ACMHA Accreditation Organization Workgroup. 2000

Deinstitutionalization Demythologized, Hospital and Community Psychiatry, 1983

Passive Immunity in the Northern Elephant Seal, American Journal of Veterinary Medicine, 1973

Inhibition of DNase 1 by Hydroxybiphenyls, Biochimica Biophysica Acta, 1971

HONORS AND AWARDS:

2006 Distinguished Fellow, American Psychiatric Association

2003-2005 California Health Care Foundation Leadership Program

1981-1983 Robert Wood Johnson Clinical Scholar

1980-1982 Ginzburg Fellowship, Group for the Advancement of Psychiatry

1974-1978 U.S. Public Health Service Scholarship

1972 University of California President's Scholarship Award

1972 University of California President's Award for Undergraduate Research`